Haemonetics (DE:HAZ)

NYSE:HAZ

HAZ

Haemonetics

RESEARCH TOOLSreports

Haemonetics (HAZ) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HAZ Analyst Ratings

Moderate Buy

5 Buy

3 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Haemonetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HAZ Stock 12 Month Forecast

Average Price Target

€67.53

▲(29.86% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is €67.53 with a high forecast of €78.34 and a low forecast of €54.58. The average price target represents a 29.86% change from the last price of €52.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"€39","49":"€49","59":"€59","69":"€69","79":"€79"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78.34224288,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€78.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.52774386285714,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€67.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.57549504,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€54.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,49,59,69,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.5,59.10324945230769,60.70649890461539,62.30974835692308,63.91299780923077,65.51624726153847,67.11949671384616,68.72274616615385,70.32599561846153,71.92924507076923,73.53249452307692,75.13574397538461,76.73899342769231,{"y":78.34224288,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.5,58.271364912527474,59.04272982505494,59.814094737582415,60.58545965010989,61.35682456263736,62.12818947516483,62.899554387692305,63.67091930021978,64.44228421274725,65.21364912527471,65.98501403780219,66.75637895032966,{"y":67.52774386285714,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.5,57.27503808,57.05007616,56.82511424,56.60015232,56.3751904,56.15022848,55.92526656,55.70030464,55.47534272,55.2503808,55.02541888,54.80045696,{"y":54.57549504,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€78.34

Average Price Target€67.53

Lowest Price Target€54.58

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Marie Thibault

BTIG

€73.94

Buy

42.19%

Upside

Reiterated

06/26/26

Analysts Conflicted on These Healthcare Names: Haemonetics (NYSE: HAE) and Health Catalyst (NASDAQ: HCAT)

Anthony Petrone

Mizuho Securities

€61.62→€74.82

Buy

43.89%

Upside

Reiterated

06/15/26

Haemonetics price target raised to $85 from $70 at MizuhoHaemonetics price target raised to $85 from $70 at Mizuho

Travis Steed

Bank of America Securities

€70.42

Buy

35.42%

Upside

Reiterated

06/05/26

Haemonetics: Buy Rating Reiterated as New Apheresis Reporting Boosts Transparency; $80 Price Target Maintained

Joanne Wuensch

Citi

€56.34→€61.62

Hold

18.50%

Upside

Reiterated

05/29/26

Haemonetics price target raised to $70 from $64 at CitiHaemonetics price target raised to $70 from $64 at Citi

Michael Petusky

Barrington

€82.74→€78.34

Buy

50.66%

Upside

Reiterated

05/12/26

Haemonetics price target lowered to $89 from $94 at BarringtonHaemonetics price target lowered to $89 from $94 at Barrington

David Rescott

Robert W. Baird

€63.38→€58.98

Buy

13.42%

Upside

Reiterated

05/08/26

Haemonetics price target lowered to $67 from $72 at BairdHaemonetics price target lowered to $67 from $72 at Baird

Rohin K Patel

J.P. Morgan

€65.14→€54.58

Hold

4.95%

Upside

Assigned

05/08/26

Haemonetics price target lowered to $62 from $74 at JPMorganHaemonetics price target lowered to $62 from $74 at JPMorgan

Michael Matson

Needham

―

Hold

―

Reiterated

05/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Haemonetics (NYSE: HAE), Scholar Rock Holding (NASDAQ: SRRK) and Ocugen (NASDAQ: OCGN)

Andrew Cooper

Raymond James

€92.43→€68.66

Buy

32.04%

Upside

Downgraded

08/11/25

Haemonetics downgraded to Outperform from Strong Buy at Raymond JamesHaemonetics downgraded to Outperform from Strong Buy at Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Marie Thibault

BTIG

€73.94

Buy

42.19%

Upside

Reiterated

06/26/26

Analysts Conflicted on These Healthcare Names: Haemonetics (NYSE: HAE) and Health Catalyst (NASDAQ: HCAT)

Anthony Petrone

Mizuho Securities

€61.62→€74.82

Buy

43.89%

Upside

Reiterated

06/15/26

Haemonetics price target raised to $85 from $70 at MizuhoHaemonetics price target raised to $85 from $70 at Mizuho

Travis Steed

Bank of America Securities

€70.42

Buy

35.42%

Upside

Reiterated

06/05/26

Haemonetics: Buy Rating Reiterated as New Apheresis Reporting Boosts Transparency; $80 Price Target Maintained

Joanne Wuensch

Citi

€56.34→€61.62

Hold

18.50%

Upside

Reiterated

05/29/26

Haemonetics price target raised to $70 from $64 at CitiHaemonetics price target raised to $70 from $64 at Citi

Michael Petusky

Barrington

€82.74→€78.34

Buy

50.66%

Upside

Reiterated

05/12/26

Haemonetics price target lowered to $89 from $94 at BarringtonHaemonetics price target lowered to $89 from $94 at Barrington

David Rescott

Robert W. Baird

€63.38→€58.98

Buy

13.42%

Upside

Reiterated

05/08/26

Haemonetics price target lowered to $67 from $72 at BairdHaemonetics price target lowered to $67 from $72 at Baird

Rohin K Patel

J.P. Morgan

€65.14→€54.58

Hold

4.95%

Upside

Assigned

05/08/26

Haemonetics price target lowered to $62 from $74 at JPMorganHaemonetics price target lowered to $62 from $74 at JPMorgan

Michael Matson

Needham

―

Hold

―

Reiterated

05/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Haemonetics (NYSE: HAE), Scholar Rock Holding (NASDAQ: SRRK) and Ocugen (NASDAQ: OCGN)

Andrew Cooper

Raymond James

€92.43→€68.66

Buy

32.04%

Upside

Downgraded

08/11/25

Haemonetics downgraded to Outperform from Strong Buy at Raymond JamesHaemonetics downgraded to Outperform from Strong Buy at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Haemonetics

3 Months

Anthony PetroneMizuho Securities

Success Rate

22/45 ratings generated profit

Average Return

+1.01%

Copying Anthony Petrone's trades and holding each position for 3 Months would result in 48.89% of your transactions generating a profit, with an average return of +1.01% per trade.

1 Year

Anthony PetroneMizuho Securities

Success Rate

26/45 ratings generated profit

Average Return

+7.00%

Copying Anthony Petrone's trades and holding each position for 1 Year would result in 57.78% of your transactions generating a profit, with an average return of +7.00% per trade.

2 Years

Anthony PetroneMizuho Securities

Success Rate

20/45 ratings generated profit

Average Return

+24.50%

Copying Anthony Petrone's trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of +24.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HAZ Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HAZ has received 9 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. HAZ average Analyst price target in the past 3 months is 67.53.

Each month's total comprises the sum of three months' worth of ratings.

HAZ Financial Forecast

HAZ Earnings Forecast

Next quarter’s earnings estimate for HAZ is €0.94 with a range of €0.89 to €0.98. The previous quarter’s EPS was €1.11. HAZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HAZ has Performed in-line its overall industry.

HAZ Sales Forecast

Next quarter’s sales forecast for HAZ is €284.16M with a range of €276.10M to €295.29M. The previous quarter’s sales results were €299.21M. HAZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HAZ has Performed in-line its overall industry.

HAZ Stock Forecast FAQ

What is DE:HAZ’s average 12-month price target, according to analysts?

Based on analyst ratings, Haemonetics’s 12-month average price target is 67.53.

What is DE:HAZ’s upside potential, based on the analysts’ average price target?

Haemonetics has 29.86% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Haemonetics a Buy, Sell or Hold?

Haemonetics has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 3 hold ratings and 0 sell ratings.

What is Haemonetics’s share price target?

The average share price target for Haemonetics is 67.53. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €78.34 ,and the lowest forecast is €54.58. The average share price target represents 29.86% Increase from the current price of €52.

What do analysts say about Haemonetics?

Haemonetics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Haemonetics?

To buy shares of DE:HAZ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Haemonetics (HAZ) Stock Forecast & Price Target

HAZ Analyst Ratings

HAZ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Haemonetics

HAZ Analyst Recommendation Trends

HAZ Financial Forecast

HAZ Earnings Forecast

HAZ Sales Forecast

HAZ Stock Forecast FAQ

Detailed List of Analyst Forecasts